1. Passport Potash (PPI:TSXV) – Significant Catalysts Achieved

Generally speaking, in mining, it is a truism that size does matter. While the tonnage of a given project is not the most important factor (by a long shot), a larger project can help get a junior miner “on the radar” of a major. With the typical exit strategies for juniors either being a path to commercial production or a takeout, a project with the benefits of size and grade can help ensure favorable economics and help junior company executives realize their vision. We have heard many times of high grade or well managed projects that major producers won’t touch because they don’t positively affect their balance sheets.

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]

SAN DIEGO - October 9, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO Jim Joyce will present at the RedChip 15th Annual Fall Small-Cap Conference this Thursday, October 11, 2012 at the Palace Hotel in San Francisco. A live webcast of the presentation will begin at 2:15 p.m. Pacific time (5:15 p.m. Eastern time) and can be accessed online here.

The webcast and archived replay of the company's presentation will be available approximately one week following the presentation at www.redchip.com/conference.

MONTREAL - October 9, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has received the Scale-Up Manufacturing Protocol from the Contract Manufacturing Organization (CMO) and is now poised to begin the process of manufacturing gram quantities of Adva-27a in preparation for conducting initial IND-Enabling studies. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR). Initial or Pre-IND-Enabling studies include a variety of in vitro biological tests as well as studies in live rats and mice in order to ascertain that the scale-up manufacturing process generates a compound that is identical to the original used in the pre-clinical studies.

New York, NY- October 5, 2012 (www.Investorideas.com Newswire, www.techsectorstocks.com ) Investor Ideas,, a global investor research portal for independent investors, issues a tech stock trading alert for social media stock Groupon, Inc. (NasdaqGS GRPN),  trading $5.2350, gaining   0.4350 or 9.06% as of  3:28PM EDT on over 16 Million shares. The stock had a day high of $5.37 .

Groupon, launched in November 2008 in Chicago, features a daily deal on the best stuff to do, eat, see and buy in 48 countries around the world. Groupon uses collective buying power to offer huge discounts and provide a win-win for business and consumers, delivering more than 1,000 daily deals globally. To subscribe for the best deals in your city, visit http://www.groupon.com. http://www.grouponworks.com.